Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3407 - Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Date

10 Oct 2016

Session

Poster display

Presenters

Neil Iyengar

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

N.M. Iyengar1, L. Smyth2, D. Lake2, A. Gucalp2, J. Singh2, T.A. Traina2, P. Defusco2, M.N. Dickler2, M. Fornier2, S. Goldfarb2, K. Jhaveri2, A. Latif2, S. Modi2, T. Troso-Sandoval2, G. Ulaner3, M. Jochelson3, J. Baselga2, L. Norton2, C. Hudis2, C. Dang2

Author affiliations

  • 1 Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 3 Radiology, Memorial Sloan Kettering Cancer Center, New York/US
More

Resources

Abstract 3407

Background

The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown.

Methods

This is a single arm phase II trial of gemcitabine (G) with HP. Eligible patients had HER2-positive (IHC 3+ or FISH > 2.0) MBC with prior HP-based treatment and ≤ 3 prior chemotherapies. Patients received G (1200 mg/m2) on days 1 and 8 of a q 3 week (w) cycle, and H (8 mg/kg load  →  6 mg/kg) and P (840 mg load  →  420 mg) q3w. The primary endpoint is PFS at 3 months. Secondary endpoints include OS, safety and tolerability. An exploratory endpoint is to compare PFS by RECIST criteria versus 18-F FDG-PET response criteria. Using a Simon optimal 2-stage design, 21 patients were enrolled in stage 1. The successful 3-month PFS rate for stage 1 was set at 57% to allow accrual to stage 2 for a total of 45 patients. The study therapy will be considered successful if at least 27/45 (60%) patients are progression free at 3 months.

Results

As of April 11, 2016, 22 patients are enrolled; 17 are evaluable at 3 months and 5 have not had 3-month evaluation. At 3 months, 12/17 (71%) are progression free (1 CR, 4 PR, 7 SD); 5 patients have progressed. The 3 month-PFS results for evaluable patients will be updated. There are no cardiac or febrile neutropenic events to date. 5 patients required G dose reduction (4 due to grade 3 neutropenia and 1 due to grade 3 vomiting) and the study was amended to lower initial G dose to 1000 mg/m2.

Conclusions

The preliminary 3 month-PFS is 71% in evaluable patients, and updated data will be presented. These findings suggest clinical benefit when P is continued beyond progression.

Clinical trial identification

NCT02252887 September 26, 2014

Legal entity responsible for the study

Memorial Sloan Kettering Cancer Center

Funding

Genentech/Roche

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings